Compass Therapeutics, Inc.
Recent Filings
All 338 filings →| Form | Description | Date |
|---|---|---|
| S-8 | S-8 | Mar 12, 2026 |
| 10-K | FORM 10-K | Mar 5, 2026 |
| 8-K | FORM 8-K | Mar 5, 2026 |
| SCHEDULE 13G/A | — | Feb 13, 2026 |
| 4 | — | Feb 10, 2026 |
| SCHEDULE 13G | — | Jan 21, 2026 |
| 4 | — | Jan 12, 2026 |
| EFFECT | — | Jan 7, 2026 |
| 8-K | FORM 8-K | Jan 6, 2026 |
| 4 | — | Jan 5, 2026 |
Insider Transactions
View all →| Insider | Title | Type | Shares | Owns After | Date |
|---|---|---|---|---|---|
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 10,000 @ $2.11 | 6,480,825 | May 27, 2025 |
| GORDON CARL L | — | Sale | 3,571,428 @ $1.59 | — | Apr 9, 2025 |
| OrbiMed Capital GP VI LLC | — | Sale | 3,571,428 @ $1.59 | — | Apr 9, 2025 |
| Anderman Jonathan | Gen Counsel & Corporate Sec | Purchase | 20,000 @ $1.54 | 21,000 | Apr 7, 2025 |
| Lerner Neil | CHIEF ACCOUNTING OFFICER | Purchase | 20,000 @ $1.42 | 320,000 | Apr 7, 2025 |
| Shin Barry | CFO | Award / Grant | 400,000 @ $1.65 | 400,000 | Dec 9, 2024 |
| Bisker-Leib Vered | Chief Executive Officer | Award / Grant | 1,753,125 @ $1.93 | 3,173,624 | Jan 9, 2024 |
| Schuetz Thomas J. | President of R&D | Award / Grant | 637,500 @ $1.93 | 6,615,348 | Jan 9, 2024 |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 10,000 @ $3.37 | 6,021,873 | Mar 10, 2023 |
| Schuetz Thomas J. | CHIEF EXECUTIVE OFFICER | Purchase | 20,000 @ $3.98 | 6,011,873 | Feb 27, 2023 |